Related Experiment Video

Updated: Jan 27, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K

Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13

Lin Chen1, Weifeng Hu1, Guohao Li1

  • 1Department of Urology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Jiang'an District, Wuhan, 430014 China.

Cellular & Molecular Biology Letters
|March 23, 2019
PubMed
Abstract

Insights

Inhibiting microRNA-9-5p (miR-9-5p) suppresses prostate cancer progression by increasing StarD13 expression. This finding suggests miR-9-5p inhibition as a potential therapeutic strategy for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer is a significant health concern.
  • The role of microRNAs in cancer progression is increasingly recognized.
  • MicroRNA-9-5p (miR-9-5p) and Star-related lipid transfer domain containing 13 (StarD13) are implicated in cancer, but their specific interaction in prostate cancer requires elucidation.

Purpose of the Study:

  • To investigate the effect of inhibiting miR-9-5p on StarD13 expression in prostate cancer.
  • To determine the impact of miR-9-5p inhibition on prostate cancer cell behavior, including proliferation, invasion, and migration.
  • To identify StarD13 as a direct target of miR-9-5p.

Main Methods:

  • Quantitative RT-PCR and Western blot were used to measure miR-9-5p and StarD13 mRNA and protein levels in prostate cancer cell lines (DU145, PC-3).
  • Cell viability, invasion, and migration were assessed using CCK8, invasion, and wound-healing assays, respectively.
  • Luciferase reporter assays and overexpression studies were conducted to confirm the regulatory relationship between miR-9-5p and StarD13.

Main Results:

  • miR-9-5p was found to be highly expressed while StarD13 was suppressed in prostate cancer cells.
  • Inhibition of miR-9-5p significantly reduced prostate cancer cell viability, invasion, and migration.
  • Overexpression of StarD13 mimicked the effects of miR-9-5p inhibition, suppressing cancer cell proliferation and metastasis, confirming StarD13 as a direct target of miR-9-5p.

Conclusions:

  • miR-9-5p promotes prostate cancer growth, invasion, migration, and epithelial-mesenchymal transition (EMT) by downregulating StarD13.
  • Targeting miR-9-5p represents a promising therapeutic strategy for prostate cancer, acting as a tumor suppressor.
Keywords:
InvasionMigrationProstate cancerStarD13microRNA-9-5p

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.8K
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.8K